Full-Time
Posted on 1/20/2025
Develops and manufactures vaccines and medicines
Entry
No H1B Sponsorship
Dorking, UK
Applicants must be completing placement as part of a degree course at a UK University.
You match the following Pfizer's candidate preferences
Employers are more likely to interview you if you match these preferences:
Pfizer focuses on creating and producing healthcare products, particularly medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then manufactured and sold globally. Pfizer's products include vaccines, cancer treatments, and other specialized medications. A key aspect of Pfizer's operations is its collaboration with BioNTech to develop a vaccine for COVID-19, which has played a significant role in addressing the pandemic. Unlike many competitors, Pfizer emphasizes its commitment to public health by providing vaccines to underserved communities and continuously expanding its product offerings through new approvals. The goal of Pfizer is to improve health outcomes worldwide by delivering effective healthcare solutions.
Company Size
10,001+
Company Stage
IPO
Total Funding
$3.8B
Headquarters
New York City, New York
Founded
1849
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Colorcon Ventures joins a prominent list of investors who also participated in Vedanta’s fundraising round, including AXA IM Alts, The AMR Ac
Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management &a
11/10/2023 Nota de prensa GOMAB, PARTICIPADA DE ASABYS, CIERRA UNA SERIES C DE $100M CON FIDELITY, EQT LIFE SCIENCES, CANAAN, KKR, ASABYS Y PFIZER Agomab Therapeutics NV(‘Agomab’) ha anunciado hoy el cierre de una ronda de financiación Serie C de 100 millones de dólares liderada por Fidelity Management & Research Company (FMR), con la participación…
New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical...
The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.
CellCentric, a Cambridge, UK- and and Manchester, UK-based biotechnology company, received a $25M strategic investment from Pfizer.Pfizer will support the company with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific haematological malignancies, through its Pfizer Ignite offering.Led by CEO Will West, CellCentric focuses on twin acetyl transferase proteins, p300 and CBP, that act as transcription co-activation factors, and that drive the expression of genes important in cancer progression. The company, which has investigated over 50 epigenetic-related targets as new ways to treat disease, and specifically cancer, was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of epigenetics to deliver new treatments. In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.Inobrodib works by binding to a specific part of proteins p300 and CBP (bromodomain). It is highly selective and does not impact similar pockets on other proteins. Through this action inobrodib reduces the expression of key cancer drivers: IRF4, MYC, and the androgen receptor (AR and its variants).In June 2023, CellCentric was granted orphan drug and fast track designation status from the FDA for inobrodib.As part of the collaboration, Astrid Ruefli-Brasse, Vice President, Tumour Biology, Pfizer Worldwide Research Development, will join CellCentric’s Scientific Advisory Board and Sriram Krishnaswami, Vice President and Development Head, Multiple Myeloma, Pfizer Global Product Development, will serve as an advisor to CellCentric.FinSMEs23/07/2023
TIAA Trust National Association invests $17.55 million in Pfizer Inc. (NYSE:PFE).
The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.
CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our
Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The